Skip to main content
SpringerLink
Log in
Book cover

Thrombolytic Therapy for Acute Stroke pp 65–76Cite as

Preclinical Testing of Thrombolytic Therapy for Acute Ischemic Stroke

  • Chapter

  • 543 Accesses

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Prior to definitive human trials, considerable effort was expended in the laboratory perfecting thrombolytic therapy. The essential literature that provided the experimental impetus for proceeding to human trials is summarized in this chapter. From this experience, two important lessons emerged. First, thorough exploration of drug risks and benefits should be performed in relevant animal models prior to human trials. Second, animal models can predict human results accurately, but only if the correct models are chosen, and the results handled rigorously. For example, the experimental data clearly predicted the efficacy, and the side effects, of thrombolytic therapy with tissue plasminogen activator (t-PA). Furthermore, the excessive risk associated with streptokinase (SK) was predicted by the animal models. These data serve to illuminate an approach to studying putative stroke therapies in the future.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Del Zoppo GJ, Copeland BR, Waltz TA, et al. The beneficial effect of intracarotid urokinase on acute stroke in a baboon model. Stroke 1986;17:638–643.

    PubMed  Google Scholar 

  2. Whisnant JP, Millikan CH, Seikert RG. Cerebral infarction and fibrinolytic agents. Roberts HR, Gevatz JD, eds. Proceedings of the Conference on Thrombolytic Agents, Chicago. 1970; pp. 235–245.

    Google Scholar 

  3. Centeno RS, Hackney PB, Rothsock Jr. Streptokinase clot lysis in acute occlusions of the cranial circulation: Study in rabbits. Am J Neuroradiol 1985;6:589–594.

    PubMed  CAS  Google Scholar 

  4. Hirschberg M, Hofferberth B. Rapid fibrinolysis at different time intervals in a canine model of acute stroke. Stroke 1987;18:292 (abstr).

    Google Scholar 

  5. Hirschberg M, Hofferberth B. Thrombolytic therapy with urokinase and prourokinase in a canine model of acute stroke. Neurology 1987;37:133 (abstr).

    Google Scholar 

  6. Hirschberg M, Korves M, Koc I, et al. Thrombolysis of cerebral thromboembolism by urokinase in an animal model. Schweiz Med Wochenschr 1987;117:1811–1813.

    PubMed  CAS  Google Scholar 

  7. Slivka A, Pulsinelli W. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke 1987;18:1148–1156.

    PubMed  CAS  Google Scholar 

  8. DeLey G, Weyne J, Demeester G, et al. Experimental thromboembolic stroke by positron emission tomography: Immediate versus delayed reperfusion by fibrinolysis. J Cereb Blood Flow Metab 1988;8:539–545.

    CAS  Google Scholar 

  9. Lyden PD, Madden KP, Clark WM, Zivin JA, et al. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits. Stroke 1990;21: 1589–1593.

    PubMed  CAS  Google Scholar 

  10. Meyer JS, Gilroy J, Barnhart ME, et al. Therapeutic thrombolysis in cerebral thromboembolism. In:, Siekert W, Whisnant JP, eds., Cerebral Vascular Diseases. Grune & Stratton: Philadelphia. 1963; pp. 160–175.

    Google Scholar 

  11. DeLey G, Weyne I, Demeester G, et al. Streptokinase treatment versus calcium overload blockade in experimental thromboembolic stroke. Stroke 1989;20:357–361.

    CAS  Google Scholar 

  12. Zivin JA, Fisher M, DeGirolami U, et al. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 1985;230:1289–1292.

    Article  PubMed  CAS  Google Scholar 

  13. Zivin JA. Thrombolytic therapy for stroke. In: Current Neurosurgical Practice, Weinstein PR, Faden AL, eds. Protection of the brain from ischemia. Williams & Wilkins: Baltimore. 1990; pp. 231–236.

    Google Scholar 

  14. Del Zoppo GJ, Copeland BR, Hacke W, et al. Intracerebral hemorrhage following rt-PA infusion in a primate stroke model. Stroke 1988;19:134,(abstr).

    Google Scholar 

  15. Zivin JA, Lyden PD, DeGirolami U, et al. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol 1988;45:387–391.

    PubMed  CAS  Google Scholar 

  16. Lyden PD, Zivin JA, Clark WA, et al. Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits. Neurology 1989;39: 703–708.

    PubMed  CAS  Google Scholar 

  17. Lyden PD, Madden KP, Clark WM, et al. Incidence of cerebral hemorrhage after antifibrinolytic treatment for embolic stroke. Stroke 1990;21:1589–1593.

    PubMed  CAS  Google Scholar 

  18. Benes V, Zabranski JM, Boston M, et al. Effect of intraarterial antifibrinolytic agents on autologous arterial emboli in the cerebral circulation of rabbits. Stroke 1990;21:1594–1599.

    PubMed  CAS  Google Scholar 

  19. Del Zoppo GJ, Copeland BR, Andercheck K, et al. Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. Stroke 1990;21:596–601.

    PubMed  Google Scholar 

  20. Vaughn DF, DeClerck PJ, De Mol, et al. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. J Clin Invest 1989;84:586–591.

    Article  Google Scholar 

  21. Chehrazi BB, Seibert JA, Hein L, et al. Differential effect of tPA induced thrombolysis in the CNS and the systemic arteries. Stroke 1989;20:153, (abstr).

    Google Scholar 

  22. Fears R. Biochemical pharmacology and therapeutic aspects of thrombolytic agents. Pharmacol Rev 1990; 42:202–222.

    Google Scholar 

  23. Phillips DA, Fisher M, Smith TW, et al. The effects of a new tissue plasminogen activator analogue Fb-Fb-CF, on cerebral reperfusion in a rabbit embolic stroke model. Ann Neurol 1989;25:281–285.

    Article  PubMed  CAS  Google Scholar 

  24. Phillips DA, Fisher M, Davis MA, et al. Delayed treatment with a tPA analogue and streptokinase in a rabbit embolic stroke model. Stroke 1990;21:602–605.

    PubMed  CAS  Google Scholar 

  25. Fisher M, Phillips DA, Smith TW, et al. Early and delayed thrombolytic therapy in rabbit cerebral embolization model using a tPA analogue. In:, Ginsberg MD, Dietrich WD, eds., Cerebrovascular Disease. Raven: New York. 1989; pp. 29–32.

    Google Scholar 

  26. Chapman D, Lyden P, Lapchak A, Nunez S, Thibodeaux H, Zivin J. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke 2001; 32:748–752.

    PubMed  CAS  Google Scholar 

  27. Ross A. New plasminogen activators: a clinical review. Clinical Cardiol. 1999;22:165–171.

    CAS  Google Scholar 

  28. Verstraete M, Lijnen H, Collen D. Thrombolytic agents in development. Drugs 1995;50:29–39.

    PubMed  CAS  Google Scholar 

  29. Zhang RL, Zhang L, Jiang A, Zhang ZG, Goussev A, Chopp M. Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat. Brain Research 2000;878:64–71.

    Article  PubMed  CAS  Google Scholar 

  30. Binbrek A, Rao N, Absher PM, Vande Werf F, Sobel B. The relative rapidity of recanalizaiton induced by recombinant tissue-type plasminogen activator (r-tPA) and TNK-tPA, assessed with enzymatic methods. Coronary Artery Disease 2000;11:429–435.

    Article  PubMed  CAS  Google Scholar 

  31. Lapchak PA, Araujo DM, Zivin JA. Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Experimental Neurology 2004;185:154–159.

    Article  PubMed  CAS  Google Scholar 

  32. Rabasseda X. Tenecteplase (TNK tissue plasminogen activator): a new fibrinolytic for the acute treatment of myocardial infarction. Drugs Today 2001;37:749–760.

    Article  PubMed  CAS  Google Scholar 

  33. Lapchak P. Development of thrombolytic therapy for stroke: a perspective. Expert Opin. Investig. Drugs 2002;11:1623–1632.

    CAS  Google Scholar 

  34. Bringmann P, Gruber D, Liese A, Toschi L, Krätzschmar J, Schleuning, W-D, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators J Biol Chem 1995;270: 25596–25603.

    Article  PubMed  CAS  Google Scholar 

  35. Toschi L, Bringmann P, Petri T, Donner P, Schleuning W-D. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators. Eur J Biochem 1998;252: 108–112.

    Article  PubMed  CAS  Google Scholar 

  36. Stewart RJ, Fredenburgh§ JC, Weitz JI. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activiators with fibrinogen, fibrin, and the complex of d-dimer noncovalently linked to fragment E. J Biol Chem 1998;273:18,292–18,299.

    Article  PubMed  CAS  Google Scholar 

  37. Liberatore GT, Samson A, Bladin C, Schleuning W-D, Medcalf R. Vampire bat salivary plasminogen activator (Desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34: 537–543.

    Article  PubMed  CAS  Google Scholar 

  38. Gardell SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991;84:244–253.

    PubMed  CAS  Google Scholar 

  39. Montoney M, Gardell S, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995;91: 1540–1544.

    PubMed  CAS  Google Scholar 

  40. Hare, TR, Gardell SJ. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation. Thromb Haemost 1992;68:165–169.

    PubMed  CAS  Google Scholar 

  41. Mellott MJ, Ramjit DR, Stabilito II, Hare TR, Senderak ET, Lynch JJ, Gardell SJ. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model. Thromb Haemost 1994;73:478–483.

    Google Scholar 

  42. Hacke W, Albers G, Al-Rawi Y, et al. for The DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). Stroke 2005;36. In press.

    Google Scholar 

  43. Gardell ST. The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk. Toxicol Pathol 1993;21:190–198.

    Article  PubMed  CAS  Google Scholar 

  44. Schleuning, W-D. Vampire bat plasminogen activator DSPA-Alpha-1 (Desmoteplase): a thrombolytic drug optimized by natural selection. Heamostasis 2001;31:118–122.

    Article  CAS  Google Scholar 

  45. Sakharav DV, Barrett-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost 1999;81:601–12.

    Google Scholar 

  46. Witt W, Mass B, Baldas B, Hildebrand M, Donner P, Schleuning W-D: Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Circulation 1995;9:91–96.

    Google Scholar 

  47. Morimoto N, Hashimoto H, Kosaka F. Effect of heparin-urokinase on brain damage induced by cerebral ischemia in dogs. Stroke 1989;20:154, (abstr).

    Google Scholar 

  48. Barsan WG, Brott TG, Olinger CP, et al. Identification and entry of the patient with acute cerebral infarction. Ann Emerg Med 1988;17:1192–1195.

    Article  PubMed  CAS  Google Scholar 

  49. Alexander, LF, Yamamoto Y. Ayoubi S. et al. Efficacy of tissue plasminogen activator in the lysis of thrombosis of the cerebral venous sinus. Neurosurgery 1990;26:559–564.

    Article  PubMed  CAS  Google Scholar 

  50. Segal R, Dejouny M, Nelson D, et al. Local urokinase treatment for spontaneous intracerebral hematoma. Clin Res 1982;30:412A, (abstr).

    Google Scholar 

  51. Weinstein PR, Anderson GG, Telles DA. Neurological deficit and cerebral infarction after temporary middle cerebral artery occlusion in unanesthesized cats. Stroke 1986;17:318–324.

    PubMed  CAS  Google Scholar 

  52. Boisvert DP, Gelb AW, Tang C, et al. Brain tolerance to middle cerebral artery occlusion during hypotension in primates. Surg Neurol 1989;31:6–13.

    Article  PubMed  CAS  Google Scholar 

  53. Collins RC, Dobkin BH, Choi DW. Selective vulnerability of the brain: New insights into the pathophysiology of stroke. Ann Intern Med 1989;110:992–1000.

    PubMed  CAS  Google Scholar 

  54. Crowell RM, Olsson Y, Klatzo I et al. Temporary occlusion of the middle cerebral artery in the monkey: Clinical and pathological observations. Stroke 1970;1:439–448.

    PubMed  CAS  Google Scholar 

  55. Penar PL, Greer CA. The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia. Yale J Biol Med 1987;60:233–243.

    PubMed  CAS  Google Scholar 

  56. Kissel P, Chchrazi B, Seibert JA, et al. Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type plasminogen activator. J Neurosurg 1987;67:399–405.

    PubMed  CAS  Google Scholar 

  57. Watson BD, Prado R, Dietrich W, et al. Mitigation of evolving cortical infarction in rats by recombinant tissue plasminogen activator following photochemically induced thrombosis. In: Raichle ME, Powers WJ eds. Cerebrovascular Diseases. New York: Raven 1987;317-330.

    Google Scholar 

  58. Papadopulous SM, Chandler WF, Salamat MS, et al. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg 1987;67:394–398.

    Google Scholar 

  59. Chechraza BB, Seibert JA, Kissel P. Evaluation of recombinant tissue plasminogen activator in embolic stroke. Neurosurgery 1989;24:355–360.

    Article  Google Scholar 

  60. Phillips DA, Fisher M, Smith TW, et al. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Ann Neurol 1988;23:391–394.

    Article  PubMed  CAS  Google Scholar 

  61. Phillips DA, Davis MA, Fisher M. Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit. Am J Neuradiol 1988;9:899–902.

    CAS  Google Scholar 

  62. Bednar MM, McAuliffe M, Raymond S, et al. Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke. Stroke 1990;21:1705–1709.

    PubMed  CAS  Google Scholar 

  63. Terashi A, Kobayashi Y, Katayama Y, et al. Clinical effects and basic studies of thrombolytic therapy on cerebral thrombosis. Semin Thromb Hemost 1990;16:236–241.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stroke Program, Department of Neurology, The Mount Sinai School of Medicine and Medical Center, New York, NY

    Steven R. Levine MD

Authors
  1. Steven R. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. USCD Stroke Center, University of California, San Diego

    Patrick D. Lyden MD

  2. Veteran’s Affairs Medical Center, San Diego, CA

    Patrick D. Lyden MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Levine, S.R. (2005). Preclinical Testing of Thrombolytic Therapy for Acute Ischemic Stroke. In: Lyden, P.D. (eds) Thrombolytic Therapy for Acute Stroke. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-933-8:65

Download citation

  • DOI: https://doi.org/10.1385/1-59259-933-8:65

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-398-5

  • Online ISBN: 978-1-59259-933-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation